BioNTech beginnt öffentliches Umtauschangebot für alle ausstehenden Aktien von CureVac N.V. Geplante Übernahme soll Forschung, Entwicklung, Herstellung und Kommerzialisierung von mRNA-basierten Krebsimmuntherapie-Kandidaten stärken und ist ein weiterer Meilenstein in der Umsetzung von BioNTechs Onkologie-StrategieCureVac-Aktionärinnen und -Aktionäre erhalten für jede CureVac-Aktie BioNTech American Depositary Shares im Wert von ca. 5,46 US-Dollar, wobei das Umtauschverhältnis einem Anpassungsmechanismus unterliegt; ein Richtwert für das Umtauschverhältnis wird während der Laufzeit des Umtau...
BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V. Acquisition aims to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next milestone in the execution of its oncology strategyCureVac shareholders receive approximately $5.46 in BioNTech American Depositary Shares for each CureVac share, subject to a collar; an indicative exchange ratio will be available at for the duration of the exchange offerInformation on how CureVac shareholders can participate in the exchange off...
A director at Generali sold 30,000 shares at 32.963EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
Ageas: AG Real Estate looking to reduce exposure to Interparking, lower capital charges. Air France-KLM: 3Q25 a bit light? ASML: Preview 3Q25, riding the AI wave. Barco: Preview 3Q25, self-help offsets macro headwind. D'Ieteren: Belron starts to roll out static mobile recalibration. Euronext: September's seasonal recovery. Tessenderlo More focus on capital allocation and returns. TomTom: Preview 3Q25, Cost cutting offsets slow markets. Umicore: Gold inventory sale-and-lease-back
Euronext announces volumes for September 2025 Euronext announces volumes for September 2025 Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 7 October 2025 – Euronext, the leading European capital market infrastructure, today announced trading volumes for September 2025. Monthly and historical volume tables are available at this address: CONTACTS ANALYSTS & INVESTORS – Investor Relations Judith Stein 97 Margaux Kurver 03 MEDIA – Europe Andrea Monzani 13 Sandra Machado 7 Belgium Marianne Aald...
Euronext announces the launch of the voluntary exchange offer for all ATHEX shares Euronext announces the launch of the voluntary exchange offer for all ATHEX shares Euronext has received regulatory approval to launch a voluntary exchange offer to acquire all common registered ATHEX sharesAcceptance Period commences on 6 October 2025 and will end on 17 November 2025 A significant step towards a more integrated and more competitive capital market in Europe, establishing ATHEX as a financial hub in the Southeast Europe regionATHEX to join Euronext’s best-in-class trading and post-trade tech...
Euronext N.v. Has Received the Relevant Regulatory Approvals for the Commencement of the Acceptance Period of the Voluntary Share Exchange Offer for the Ordinary Registered Shares of Hellenic Exchanges-Athens Stock Exchange NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY, OR CONSTITUTE A VIOLATION OF, THE RELEVANT LAWS OF THAT JURISDICTION OR REQUIRE EURONEXT AND/OR ATHEX TO TAKE ANY FURTHER ACTION. PLEASE SEE THE IMPORTANT DISCLAIMERS AT THE END...
BioNTech veranstaltet am 1. Oktober 2025 zweiten „AI Day“ als eine Ausgabe der „Innovation Series“ MAINZ, Deutschland, 23. September 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BNTX, „BioNTech“) richtet zusammen mit ihrem Tochterunternehmen für künstliche Intelligenz (artificial intelligence, „AI“), („InstaDeep“), am Dienstag, den 1. Oktober 2025 um 15:00 Uhr MESZ (09:00 Uhr EDT) ihren zweiten „AI Day“ aus, eine Ausgabe von BioNTechs „Innovation Series“ in London, Vereinigtes Königreich. Die Veranstaltung gibt einen Überblick über die Strategie und die Fähigkeiten von BioNTech im Bereich AI und...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.